C2N Diagnostics, LLC ("C2N"), a specialty diagnostics company with a vision to bring Clarity Through Innovation®, today ...

A St. Louis-based company known for its work in Alzheimer's and neurological testing can expand its footprint, thanks to a $10 million investment from several life sciences companies.

Samsung is backing Alzheimer’s disease blood test developer C2N Diagnostics, with $10 million to help scale up its commercial ...

it has contributed to the stabilization of the biopharmaceutical supply chain and better access to high quality bio pharmaceutics. The investment into C2N Diagnostics shows Samsung’s continued ...

Jaywoo Kim, Executive Vice President of Samsung C&T Corporation, says, “Since Samsung C&T stepped into the life sciences industry by investing in biologics CDMO and biosimilar business, it has ...

C2N is currently expanding its biomarker pipeline by developing advanced assays targeting tau pathology, Parkinson’s disease research, and developing technologies to decentralize mass spectrometry ...